Books

Issues

Resources

Free Reminder

Contact Us

Newsbytes - Prostate

Prostate Cancer Awareness Week (pcaw.org) has compiled newsbytes on the prostate. Prostate Cancer Awareness Month is September, and Prostate Cancer Awareness Week, the period set aside for free or low-cost screenings, runs September 18-24, 2005. Information about the Prostate is added weekly. Disclaimer

Newsbytes


Rise in PSA Level May Predict Cancer Death

There's a new red flag for men facing prostate cancer surgery: It's called PSA velocity.
Source: my.webmd.com/content/article/90/100584.htm?action=related_link

Popular Painkiller May Slow Prostate Cancer

A commonly prescribed painkiller may slow prostate cancer growth, new research shows. Learn more.
Source my.webmd.com/content/article/88/100019.htm:

Calculate Your Odds Against Prostate Cancer

Researchers have created an online calculator that provides prostate cancer patients with personalized 10-year survival predictions. Developed by the Josephine Ford Cancer Center and the Artificial Neural Networks in Prostate Cancer Project, the calculator makes its prognosis based on a patient's age, race, clinical measures and the kind of prostate cancer treatment he's receiving. Survival probability estimates are based on data from over 1600 men with clinically localized prostate cancer.
Source: www.prostatecalculator.org  

Valera Seeks FDA Approval for Prostate Cancer Implant

Valera Pharmaceuticals has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for Vantas(TM), Valera's long-acting implant for treating prostate cancer. Vantas(TM) has been designed for the continuous 12-month administration of Histrelin, a luteinizing hormone releasing hormone (LHRH) for the palliative treatment of metastatic prostate cancer.

Herbs That Fight Prostate Cancer

A mixture of 10 herbs -- available commercially -- has been shown to fight prostate cancer in the test tube. Read on to get the full list of ingredients and to learn why they're important for men with high PSA levels and/or a family history of the disease.
Source: my.webmd.com/content/article/56/65833.htm

Drug Prevents Prostate Cancer

Risk drops 25 percent with finasteride, say researchers, but there are side effects of more aggressive tumors, impotence.
Source: www.healthcentral.com/news/NewsFullText.cfm?id=513841

A Gene That May Block Prostate Cancer's Spread

Finding could lead to genetic therapies to treat variety of cancers.
Source: www.healthcentral.com/news/NewsFullText.cfm?id=513717

Lost Protein Key to Prostate Treatment?

Northwestern researchers have found that a protein made in the body is critical for normal prostate growth regulation and could hold a key to treating prostate cancer. Researchers Jennifer Doll and Veronica Stellmach found that mice that lack the protein pigment epithelium-derived factor (PEDF) develop an enlarged prostate. They then found little to no PEDF in human prostate cancer tissue samples. The researchers then examined the effects of PEDF on cultured prostate cancer cells. They found that PEDF triggered an increased rate of prostate cancer cell death. To read more, go to
Source: www.northwestern.edu/univ-relations/media_relations/releases/2003_06/angiogenesis.html

Polymorphism May Be Associated With Prostate Cancer Risk

People who carry a polymorphism in the 102V allele of the PON1 gene may be at an increased risk of developing prostate cancer, according to a new study.
Source: Journal of the National Cancer Institute, www.intelihealth.com/IH/ihtIH/EMIHC274/333/20786/365254.html?d=dmtICNNews

The average woman's chance of dying of prostate cancer - 0.001%

You read it right: Women have prostates. And they can even develop prostate cancer, although it's rarer than rare.
Source: Men's Health Magazine, 5/03

Lifestyle linked to prostate cancer risk

In a six-year study of 1,117 patients with localised prostate cancer, researchers from the University of Texas looked at prostate specific antigen levels, the aggressiveness of the cancer - measured by a biopsy Gleason score - and the size of the tumour. The researchers discovered that patients with a high risk of progression were significantly more likely to be obese, to exercise less than twice a week and to not undergo annual prostate screening. On the contrary, those with the lowest risk kept their weight down, undertook regular exercise and were screened regularly for signs of the disease. "What we are finding has positive implications for prostate cancer prevention," according to Dr Mfon Cyrus-David of the university's department of epidemiology. "It appears to be important that men maintain a low body mass index, exercise to the point of sweating at least two times a week, and are screened regularly for prostate cancer," he says. The researchers emphasise that their conclusions are preliminary and a follow-up study is needed to validate their findings.
Source: Health Media Ltd

Thalidomide used in cancer battle

Controversial drug thalidomide is proving a success helping scientists in their fight to find a cure for prostate cancer. Around 20 terminally ill men showed signs of improvement on the drug, which caused a national scandal in the 50s and 60s when thousands of children were born with horrendous defects, many missing limbs. Now researchers believe they are well on the way to finding a cure for the disease which is the biggest cancer killer of men and claims 8,000 lives a year. The team is only the second in the world to use the drug for prostate cancer - the first in America was unsuccessful as patients suffered serious side effects because the dose was too high. The Newcastle team now plan to use it on sufferers at an earlier stage of disease to see if it will cure them. Lead researcher Dr Marcus Drake, clinical lecturer in urology at the University of Newcastle, said: "We are very excited about these findings. "Lung cancer used to be the biggest killer of men but with smoking rates going down death rates are going down and prostate cancer has taken over.

Sea Slug could Save Lives in Britain's Fight Against Prostate Cancer

A drug that is derived from a Hawaiian mollusc could save lives from prostate cancer Experts from Cancer Research UK at Edinburgh University are investigating the sea slug's anti-cancer properties in order to understand how it could prove effective as a chemotherapy drug.
Source: The Scotsman, www.ustoo.org/screamoutput/index.html

HRT Patches Helping Men With Prostate Cancer

Hormone replacement patches normally used by menopausal women have proved an effective treatment for men with advanced prostate cancer. HRT led to a regression of disease in 20 patients and improved their quality of life, said researchers who carried out a preliminary study in London. Prostate cancer is fuelled by the male hormone testosterone. When the disease spreads doctors try to hold it back by reducing the impact of the hormone. Hormonal drugs are used to cut production of testosterone or block its effect, and as a last resort the testicles are removed. But these treatments have significant side effects, including hot flushes, impotence, oesteoporosis, anaemia and breast growth. Oestrogen pills can also reduce testosterone levels but are too dangerous to use because of the risk of blood clotting. Doctors at Hammersmith Hospital and Imperial College found that within three weeks HRT patches reduced testosterone levels in the men to a point normally achieved by castration. Blood flow was good and bone density significantly stabilised or increased. Symptoms of the "andropause" - the male equivalent of the female menopause - were prevented, and quality of life generally improved. Prostate cancer generally affects men in their sixties or seventies, but doctors are seeing increasing numbers of middle-aged patients. It is the second most common cancer in men, with 24,700 people diagnosed each year in Britain. Of these, about half will die from the disease.
Source: World Entertainment News Network

Power Over Prostate

Men with localised prostate cancer may be able to stop the disease progressing if they maintain normal weight, exercise strenuously at least twice a week and have routine screenings, according to the preliminary findings of a University of Texas M D Anderson Cancer Centre study which looked at the lifestyle of 1117 men over six years. Lead author Dr Mfon Cyrus-David says: ``What we are finding has positive implications for prostate cancer prevention.'' He stressed the results needed to be validated with a follow-up study.

Fosamax Type Osteoporosis Drugs Noted to Cause Serious Eye Problems

Drugs commonly prescribed to osteoporosis and cancer patients may cause serious inflammation in several regions of the eye in some patients. Researchers hope the finding will make physicians more likely to monitor patients for such eye problems as well as prompt drug companies to add warning labels to their products. Two medications in a class of drugs called bisphosphonates, which are often used to increase bone density in patients with osteoporosis, were found to cause the serious side effects in the eyes of some patients. The drugs are also prescribed to cancer patients, as lung, breast or prostate cancer that has spread to the bones can also decrease bone density. Researchers reviewed thousands of cases in which patients were prescribed bisphosphonates and tracked 314 patients who also reported eye problems. Although the side effects were rare and did not occur in most patients, some types of eye inflammation can lead to vision loss or blindness if left untreated. Of the patients who reported side effects, close to 100 suffered from blurred vision. Other problems included pain and swelling. Researchers noted that the side effects went away when patients stopped taking the medication. New England Journal Medicine March 20,2003;348(12):1187-8
Source: Optimal Wellness Center / Mercola.com

The role of endothelin axis in cancer therapy merits further investigation

According to recent research from the United States, "Collectively, the endothelins and their receptors-referred to as the endothelin (ET) axis-have key physiological functions in normal tissue, acting as modulators of vasomotor tone, tissue differentiation, development, cell proliferation and hormone production. "Based on new data, the ET axis also functions in the growth and progression of various tumors," wrote J. Nelson and colleagues, University of Pittsburgh, School of Medicine. The researchers concluded: "Preliminary results from clinical trials, such as those with atrasentan, an ETA-receptor antagonist in prostate cancer, are encouraging. The place of ETA-receptor antagonists in cancer therapy for a range of malignancies merits further investigation." Nelson and colleagues published their study in Nature Reviews. Cancer (The endothelin axis: Emerging role in cancer. Nature Rev Cancer, 2003;3(2):110-116).
Source: NewsRx.com

A man thing

I am writing to ask your readers to join me and support Man Alive 2003 – Cancer Research UKs mens cancer awareness initiative, which will be running from May 12 until June 15, 2003.

The aim of this campaign is to raise £300,000 for research into cancers that affect men, as well as raising awareness among men about cancer and encouraging them to take care of their health.

One in three men in the UK will be diagnosed with cancer at some point in their lives – almost 130,000 every year, with prostate cancer the most common type. Cancer Research UK supports a broad programme of research into these cancers: their causes and development, prevention, early detection, treatment and quality of life of patients, funded almost entirely by public support and donations. Call 08701 602040 or register online at www.cancerresearchuk.org/manalive now to receive a fundraising pack and have fun raising money and saving lives. Sir Ian Holm, "Lord of the Rings" star.
Source: Newsquest (Wiltshire) Ltd

Sequence Matters When Using Novel Agent

An experimental agent that targets a cancer cell's protein shredding machinery (the proteasome) should be given either before or with taxane-based chemotherapy drugs, but not after, say researchers at The University of Texas M. D. Anderson Cancer Center who conducted laboratory tests using prostate cancer cells. The finding is important because the new therapy, known as PS-341 (Velcade), will likely be tried as new treatment for a number of cancers due to its effectiveness in multiple myeloma, says Christos Papandreou, M.D., Ph.D., assistant professor in the department of Genitourinary Medical Oncology. "It appears PS-341 could become quite a hit as a novel proteasome inhibitor, a drug that increases the effectiveness of chemotherapy agents," Papandreou says. "We know that while the sequence it is used in doesn't matter with certain classes of chemotherapy drugs, it does with others. Hopefully, future clinical trials will reflect this new understanding." The findings were published in the Proceedings for the 2003 Annual Meeting of the American Association for Cancer Research
Source: NEWSWISE/Medical News


NASA's Solution for Urine Control Could Help Fighter Pilots Avoid Urinal Bags; New Product Helps Men Stay Dry Despite Circumstance or Incontinence

Flying faster than the speed of sound in a $23 million F-16, our fighter pilots have to saturate in a diaper (for women) or take aim at a urinal-type bag (for men). NASA astronauts have come up with a better way. Using a product produced by Tampa Bay-based BioDerm Inc., the astronauts can stay clean and dry and can go about their tasks. The External Continence Device (ECD) for men fits only to the tip of the penis with a special hydrocolloid material. Hydrocolloid is a skin-friendly material that bonds like a second skin and is typically used in treating wounds. The ECD seals gently yet very securely and adheres for approximately 24 hours. Urine immediately flows into a tube and then a leg bag. Skin stays dry. See www.bioderm-inc.com "Our customers are NASA astronauts and men with spinal cord injury, multiple sclerosis, muscular dystrophy, recent surgery or other medical conditions who want to stay active," said Dr. Dennis Kay, CEO of BioDerm. "They are traveling salesmen, judges, engineers, executives and hunters. The product gives them freedom. And we can help fighter pilots, too."
Source: PR Newswire. For information, visit the www.BioDerm-Inc.com or call 800.373.7006

New Results in Breast and Prostate Cancer Models Show Potential of ARIUS Antibodies-Tumor Suppression and Increased Survival Following Treatment ARIUS Research Inc

ARIUS Research Inc. announced today that the proceedings of the 94th annual meeting of the American Association for Cancer Research (AACR) will publish successful pre-clinical study results for three of their novel anti-cancer antibodies. AR7BD-33-11A and AR1A245.6 have met a number of significant endpoints including preventing development of breast and prostate cancers in tumor prevention models and halting tumor growth in a different, established tumor model. These antibodies also significantly improved survival in animal models of human cancer. A third antibody, AR7BDI-58, suppressed development of another kind of breast cancer.
Source: Canada NewsWire

Inhibitors of Novel Cancer Target Attack Tumor on Two Fronts-AACR Proceedings Highlight Research of LPAAT-beta Inhibition By Cell Therapeutics, Inc. in Human Cell Models

In a plenary minisymposium on intracellular signaling published in the April 2003 issue of the Proceedings of the Annual Meeting of the American Association for Cancer Research, Cell Therapeutics, Inc. presented data on a novel cancer target, LPAAT-beta. The data suggest that the inhibition of LPAAT-beta may impede the growth of tumors on two fronts, by restricting the growth of supporting tissues such as blood vessels and by removing a cofactor essential to tumor cell growth and proliferation. Existing therapies typically use a single mechanism to fight cancer, whereas, LPAAT-beta inhibitors appear to have a dual function. In the published proceedings, CTI highlighted research on signaling pathways which showed that inhibition of LPAAT-beta by genetic knockdown with RNAi or with specific inhibitors of the enzyme leads to tumor cell death through apoptosis. CTI's research also suggests the enzyme plays an important role in cell types that are critical in the formation of the support tissues (stroma) and the abnormal blood vessels which support tumor growth and provide tumor blood supply. "The discovery of a gene product that has critical functions in the regulation of the Raf and other cancer-related pathways as well as in the tissues supporting the tumor is intriguing and suggests LPAAT-beta inhibition may be particularly effective in treating cancer where therapies that use only a single mechanism for fighting cancer have failed," said Jack W. Singer, M.D. and Research Program Chair of CTI.
Source: PR Newswire

HRT Patches for Men: They help in prostate cancer fight

Hormone patches normally worn by women to relieve menopausal symptoms are helping men fight prostate cancer. They cut the supply of the male hormone testosterone, which can encourage the growth of cancer cells, according to experts.
Source: Daily Mail. www.ustoo.org/screamoutput/index.html

External Beam Radiotherapy can Relieve Metastatic Bone Pain

"We have performed a clinical study to evaluate the relationship of response to EBRT in terms of pain relief and improvement in quality of life (QoL). We were also interested in the incidence of acute toxicity with EBRT. We have prospectively evaluated 75 patients (median age 68 years, range 64-79 years) with bone metastases from prostate cancer treated with EBRT, radiographically documented from June 1999 to September 2000," wrote G. Di Lorenzo and colleagues, University of Naples.
Source: Cancer Weekly, www.ustoo.org/screamoutput/index.html

Prostate Cancer Patients with Highest Risk of Progression

Based on a large study of prostate cancer patients, researchers are finding that maintaining a normal body mass index, frequent physical activity and screening before diagnosis appear to be important in stopping prostate cancer from progressing.
Source: Newswise/ Medical News, www.ustoo.org/screamoutput/index.html

A New Photosensitizer Advances the Use of Photodynamic Therapy for Cancer

A new photosensitizer known as Pd-bacteriopheophorbide (TOOKAD) improves the efficacy of photodynamic therapy against small cell carcinoma of the prostate. "Small cell carcinoma of the prostate (SCCP), although relatively rare, is the most aggressive variant of prostate cancer, currently with no successful treatment," explained Natalia V. Koudinova and colleagues of the Weizmann Institute of Science in Rehovot, Israel.
Source: Angiogenesis Weekly,www.ustoo.org/screamoutput/index.html

Arthritis Drug Suppresses Cancer Deveopment by Stopping Action of Key Protein

Before this study, scientists had linked use of celecoxib capsules (commonly known as Celebrex) to prevention of cancer, but the way in which the medication acted in cancer cells was unknown. Now, investigators have found that celecoxib capsules stop a key transcription factor known as Sp1 from turning on multiple genes in cancer cells known to be associated with cancer growth. One of those genes triggers production of vascular endothelial growth factor (VEGF), the predominant angiogenic factor that leads blood vessels to grow to feed tumors.
Source: Datamonitor Healthcare Newswire, www.ustoo.org/screamoutput/index.html

Emory University to Lead $10 million Project

The Winship Cancer Institute (WCI) of Emory University has been awarded a $10 million grant from the U.S. Department of Defense (DoD) Prostate Cancer Research Program. The grant will fund development of a new prostate cancer research consortium consisting of 13 universities from eight states over 3 years. Led by Jonathan Simons, MD, director of the Winship Cancer Institute (WCI) and Leland Chung, PhD, director of Emory's Molecular Urology and Therapeutics Program and a Georgia Cancer Coalition Distinguished Scholar, the consortium will work to identify entirely new therapeutic targets and concepts for effective treatment of advanced prostate cancer.
Source: Cancer Weekly, www.ustoo.org/screamoutput/index.html

Pharmagenesis enters Agreement for Anticancer Drug based on Chinese Herbs

Pharmagenesis, Inc., has signed an agreement with Pierre Fabre Medicament (PFM), a European company that has pioneered the use of natural extracts for pharmaceutical and dermatological products, to license PG490-88Na, a patented derivative of a compound from a plant widely used in Chinese medicine. Preclinical studies have shown that using PG490-88Na can significantly inhibit growth of a broad range of human tumor cells.
Source: Pharma Business Week,www.ustoo.org/screamoutput/index.html

Researchers Detect the PSA-RP2 Variant in Prostate Tissue

"PSA (prostate-specific antigen), the most useful serum marker for prostate cancer, is encoded by the hKLK3 gene and is present in the serum as a mixture of several molecular species," researchers in France report.
Source: Cancer Weekly, www.ustoo.org/screamoutput/index.html

The Antioxidant Serum Micronutrient Gamma-Tocopherol Apperas to Lower Risk

Large cohorts of normal men were tested for serum micronutrients and followed for prostate cancer development; gamma-tocopherol concentrations in serum appeared protective.
Source: Cancer Weekly, www.ustoo.org/screamoutput/index.html

Insulin-Like Growth Factor-II is a Target for Cancer Gene Therapy

According to a study from the United States, "towards understanding the insulin-like growth factor (IGF) system during cancer growth and progression, progressive prostate cancer models, such as SV40 large T antigen immortalized human prostate epithelial cells (P69, M2182, M2205, and M12) and LNCaP sublines (C4, C4-2, and C4-2B4), were used." "IGF-II mRNA levels progressively increase as prostate cancer cells become more tumorigenic and metastatic, suggesting that IGF-II contributes in part to prostate cancer progression," said N. Guo and coauthors, City of Hope National Medical Center, Beckman Research Institute.
Source: Cancer Weekly, www.ustoo.org/screamoutput/index.html

Selective Inhibition of the ETS2 Gene shows the Potential for Stopping Cancer

"The transcription factor Ets2 has a role in cancer development and represents an attractive therapeutic target. In this study, we designed a triplex-forming oligonucleotide (TFO) directed to a homopurine:homopyrimidine sequence in the Ets2 promoter. Transcription factors of the Sp family bound to this sequence and mutation of the Sp1 site reduced Ets2 promoter activity," according to recent research from the United States.
Source: Cancer Weekly, www.ustoo.org/screamoutput/index.html

Androgen Suppression Can be Discontinued in Some Prostate Cancer Patients

Withdrawing from hormonal therapy appears safe for elderly patients with advanced prostate cancer who are asymptomatic and have achieved an undetectable PSA level after prolonged androgen blockade, according to a report from the Washington Hospital Center in Washington, DC.
Source: Reuters Health

Hybrid Cancer Therapy

A group of scientists at the Scripps Research Institute (TSRI) has designed a "hybrid" anticancer compound by combining the potency of a traditional anticancer drug that targets cancer tumors with a long-lasting antibody.
Source: ScienceDaily

For Cancer Cures, the Future Starts Now

Key advances in drugs, vaccines, radiology treatment and genetics may eventually cure cancer. In the meantime, improved treatments are helping make many cancers manageable diseases instead of death sentences.
Source: Miami Herald

A New Way to Target Cancer Cells

Researchers from the University of Utah and the National Cancer Institute developed an experimental drug that reacts with a substance inside cancer cells, releasing nitric oxide to kill the cells or slow their growth without harming healthy cells.
Source: Newswise

Study Offers New Insights Into Angiogenesis Inhibitors

In working to halt the overgrowth of blood vessels that feed cancerous tumors, the antiangiogenic molecules endostatin and tumstatin take two distinct and very different tactics, according to a study from the Center for Matrix Biology at Beth Israel Deaconess Medical Center (BIDMC). The findings suggest these two agents combined may prove more effective in battling cancer than either one used separately.
Source: Newswise

Can Genetic Research Yield Cancer Cure?

Scientists can now isolate the genetic markers of cancer to find the ones that trigger the tumor. By testing drugs against those trigger genes to see how they react, scientists may create individualized cancer treatments and find the shared genetic characteristics between such diseases as lung, colon and breast cancer. This type of research has already led to the development of the highly effective leukemia drug Gleevec, which targets cancer cells, while leaving healthy tissue intact and causing few side effects.
Source:  HealthScoutNews Reporter

The Prostate Workout

"Use it or lose it" is good advice when it comes to keeping your mental skills sharp and your body in shape, but can you buff up your prostate with frequent, regular ejaculations?
Source: my.webmd.com/content/article/62/71595.htm

The Truth About the Tests You'd Rather Skip

PSAs and colonoscopies -- no guy looks forward to these screenings. A new study says which of these two tests is more effective -- and it's not the one you're most likely to get.
Source: my.webmd.com/content/article/62/71648.htm

Idea for Prostate Treatment Based on Breast Cancer Discovery

This study is based on earlier findings that tumor cells exposed to very low levels of oxygen become resistant to the killing effects of anticancer drugs. Reduced oxygen levels contribute to the drug resistance by blocking the production of nitric oxide (NO) in the tumor cells.
Source: http://www.ustoo.org/screamoutput/index.html

Fighting Cancer with a Vaccine?

In a new approach to fighting cancer, researchers are working to develop vaccines to stimulate the immune system to destroy malignant cells, without the severe side effects that often accompany radiation and chemotherapy. Clinical trials are under way to test dozens of vaccines for melanoma, lymphoma, leukemia and cancers of the colon, breast, prostate, kidney and pancreas. No cancer vaccines are in general use yet, but several are in the final stages of testing before they go before the federal Food and Drug Administration for approval. One vaccine already has been approved in Canada.
Source: http://www.ustoo.org/screamoutput/index.html

Causes of Prostate Cancer Still "Poorly Understood"

Professor Henrik Gronberg, from Sweden's Umea University, raised his concerns in a review of the epidemiology of prostate cancer, published in The Lancet. Describing the difficulties in understanding the disease, Prof Gronberg said many epidemiological studies relating to diet were "mostly conflicting and negative". However, he said there was some consensus over the relationship between diet and prostate cancer, with an association made between high intakes of alpha-linolenic acid - a polyunsaturated fatty acid found in vegetables and diary products - and calcium.
Source: http://www.ustoo.org/screamoutput/index.html

A Very Male Dilemma

When it comes to prostate cancer, the cure can be worse than the disease. It's left doctors divided and the public confused, writes Julie Robotham. ON THE face of it, there is nothing to argue about. From medicine's conservatives right through to its most gung-ho experimentalists, everyone says the same thing: a prostate cancer screening-test should be available to any man who wants it, but that nobody should be urged to take it because its possible benefits are not sufficiently clear, especially when weighed against the side effects of treatment. So what caused the extraordinary feud that reignited this week over the question of just how much information a man needs before he can soundly make that decision?
Source: http://www.ustoo.org/screamoutput/index.html

Freedom WITH Incontenence - External Incontinence Device Available

According to studies at the University of Washington and New York University Medical Center, urinary incontinence is a long-term problem for more than ten percent of patients who have a radical prostatectomy.1, 2 That percentage is probably low because many men struggle on their own without consulting their doctors. How much do doctors really understand about the day-to-day challenges and stress of living with incontinence? And it is not much comfort knowing that more than seven percent of all adults are incontinent. For the full story:
Source: www.ustoo.org/FreedomWithIncontinence.pdf

Androgen Independent Prostate Cancer (AIPC)

A study designed to evaluate the effectiveness of an innovative new treatment (an endothelin receptor antagonist) in reducing bone pain experienced by men with AIPC, who are currently taking narcotic pain medication, yet despite this, are still experiencing pain.

Men who are interested and eligible (upon medical assessment) to take part in the treatment study will also be asked to keep a pain and medication diary, and complete questionnaires to contribute towards a better understanding, and hopefully improved treatments, for others suffering from the pain resulting from AIPC. Call 866 837 9335.
Source: www.centerwatch.com/patient/studies/stu42542.html

Yearly Prostate Cancer Testing Not Necessary For Millions Of Men With Low Readings

A common blood-scanning test for prostate cancer, an annual medical ritual for millions of older men, can safely be done less frequently for the majority who have low readings, a major study concludes.
Source: www.intelihealth.com/IH/ihtIH/WSIHW000/9105/342/350221.html

Editor's Warning Label: I have a test every year. At 60 everything was fine. At 61, my PSA was elevated and I had a biopsy. No trace of cancer. At 62 it was elevated again. I had another biopsy, it was in four nodes and I had a Gleason of 3+3. Most states require a doctor to sign the order to draw blood. In Oregon, it costs $12 to draw it at the hospital, and $38.00 to send it out to an outside lab and get results. A Free PSA is another $30, which, if your PSA is over 4.0 gives you another indicator of possible cancer. An AMAS blood test indicates whether or not it has metastasized and cost the drawing fee, an overnight shipping charge in dry ice (mine was $42 from Oregon to Boston), and $135 for the actual blood test. I'd say that's pretty cheap. If your under 70 and the medical community tells you that what they can do for you really won't improve your life or extend it much, and that chances are you'll die of something else first, get a second opinion. Alternative Medicine's have positive results. Surgery and radiation extend most men's lives 10 or more years. And, while men in the higher risk categories are, in fact, at higher risk, I understand that less than 10% of the men who die from prostate cancer, not a painless death, are not in the high risk category. I would recommend the following: If you're over 40, get a PSA test. If the reading is between zero and 1, get another test in five years.. If it's between 1-2, get another one in two years, if it's over 2, get a test every year. If it's over 4, have some other tests done, like the PSA Free, before a possible biopsy. And start gathering all the knowledge you can on your possible options. Source: www.pcaw.org

Greater Height Associated With Increased Risk Of Prostate Cancer Over Age 50

Greater height appeared to be positively associated with subsequent risk of prostate cancer in men over age 50, according to a study presented at the national meeting of the American College of Preventive Medicine Meeting in San Diego.
Source: American College of Preventive Medicine, www.intelihealth.com/IH/ihtIH/WSIHW000/333/20786/361511.html
 

A Prospective Study Of Body Size Parameters And Risk Of Prostate Cancer

Using data from the Physicians Health Study of 22,071 men in the U.S., investigators looked at self-reports from 1,634 prostate cancer patients. They were trying to determine the relationship between body size parameters (height, weight, body mass index), plus age, to the risk of prostate cancer.
Source: American College of Preventive Medicine, www.intelihealth.com/IH/ihtIH/WSIHW000/333/20786/361389.html

Japanese Emperor Admitted To Hospital

Emperor Akihito was admitted to a Tokyo hospital Thursday for an operation for prostate cancer this weekend, the Imperial Household Agency said.
Source: www.intelihealth.com/IH/ihtIH/EMIHC000/333/333/360137.html

Idea for Prostate Treatment Based on Breast Cancer Discovery

This study is based on earlier findings that tumor cells exposed to very low levels of oxygen become resistant to the killing effects of anticancer drugs. Reduced oxygen levels contribute to the drug resistance by blocking the production of nitric oxide (NO) in the tumor cells.
Source: http://www.ustoo.org/screamoutput/index.html

Breast Gene Fault Increases Prostate Cancer Risk

A genetic fault that makes women more susceptible to breast and ovarian cancer also raises a man's risk of developing prostate cancer, a British scientist said Wednesday. Dr. Ros Eeles, a medical geneticist at The Institute of Cancer Research in southern, England, told a medical conference that men with an inherited defect in the BRCA 2 gene have a five-to-seven fold increased risk of prostate cancer than those without the fault. She announced plans to launch a European-wide study of 500 men who have four or more close relatives who have developed breast cancer before the age of 60. They may have inherited the mutation and would be more likely to develop prostate cancer. "We are trying to see if you can identify a high-risk group (of men) that you can target for screening," Eeles told the first annual meeting of the medical charity Cancer Research UK. Forty percent of early onset, aggressive prostate cancers are linked to inherited factors. Some are due to alterations in the BRCA 2 gene, according to Eeles. The trial, which is due to begin in December or January, will be the among the first to use genetic screening to target men in this way. "The crucial thing about screening for prostate cancer is to identify those men with a high risk of an aggressive form of the disease," Eeles added.
Sources: story.news.yahoo.com/news?tmpl=story2&cid=570&u=/nm/20021030/sc_nm/health_cancer_prostate_dc_1 and www.hopkinsprostate.com/html/pbHeadlines.html

Three Prostate Cancer Monotherapies Provide Equivalent Relapse-Free Survival

Three monotherapies for treating T1/T2 adenocarcinoma of the prostate provide similar rates of five-year biochemical relapse-free survival, suggesting that side effects, not efficacy, should be the main consideration in selecting a therapy. Dr. Louis Potters, chief of radiation oncology at Memorial Sloan-Kettering Cancer Center's Mercy Hospital, New York, United States, and colleagues presented their findings Sunday at the American Society for Therapeutic Radiology and Oncology (ASTRO) 44th Annual Meeting, in New Orleans, Louisiana. The researchers reviewed the biochemical relapse-free survival in 1,866 consecutive patients receiving permanent seed implantation (PI), external beam radiotherapy (EBRT) to a minimum 70 Gy, or radical prostatectomy (RP). All patients had clinically localized stage T1/T2 prostate cancer treated between 1992 and 1998. Three and forty eight of the patients were treated with EBRT, 783 were treated with RP, and 735 were treated PI. Over 90 percent of the patients in each treatment group were stage T1-T2a, and the rest were T2b. About three-fourths of the patients in each treatment group had an initial prostate-specific antigen (PSA) level of 10 ng/ml or less and a Gleason score of six or less. Median follow-up time was 54 months for all cases. Biochemical relapse was defined as any detectable PSA value greater than 0.2 ng/ml for patients receiving RP, or three consecutive PSA value rises for those receiving EBRT or PI. The 5-year biochemical relapse-free survival rates for cases treated with PI, EBRT, and RP were 82 percent, 77 percent, and 83 percent, respectively (p=0.082); the 7-year biochemical relapse-free survival rates were 74 percent, 77 percent and 79 percent, respectively. Multivariate analysis identified initial PSA (p<0.001), Gleason score (p<0.001), and clinical T stage (p=0.035) as independent predictors of biochemical relapse-free survival. In contrast, treatment modality, age, and race were not predictors. "We are encouraged that our results confirmed that of these others mined only monotherapy so that the results are unencumbered by adjuvant therapies such as hormones or the addition of radiation," he added. Dr. Potters continued to say that the treatment decision for a man with prostate cancer may be better based on side effects rather than that of biochemical outcome. "Further, the results imply excellent biochemical control regardless of which therapy is chosen," he added.
Source: www.docguide.com/news/content.nsf/NewsPrint/8525697700573E1885256C4D00767AED

Man's Migraine Linked to Soy Consumption

A man who increased his soy intake hoping to relieve discomfort from his ailing prostate developed migraine headaches, according to a new report. As people age they become less likely to have migraines, and new-onset migraine in older people is particularly rare, according to Dr. Peter Engel of Albany Medical College in New York. He reports the case of a 57-year-old man who mysteriously developed migraine with aura in the October issue of Neurology.
Source: www.nlm.nih.gov/medlineplus/news/fullstory_10050.html

Korean Red Ginseng May Treat Impotence

Korean red ginseng, a herb considered an aphrodisiac in some Asian countries, seems to be an effective treatment for erectile dysfunction, according to the results of a small study from Korea.
Source: www.nlm.nih.gov/medlineplus/news/fullstory_10031.html

Cancer Test Shows 100% Sensitivity and Specificit

The results of multisite clinical trials have shown that a new blood test for cancer detection, based on molecular fingerprinting, correctly identified 177 patients known to have lung, breast, gastrointestinal, or prostate cancer; and also correctly ruled out cancer in each of the 72 control patients. The data were presented at Karolinska Institute (Solna, Sweden) by Dr. Toomas Neuman, chief scientific officer of CeMines, Inc. (Evergreen, CO, USA), which developed the test. Based on the data, Karolinska has initiated a 4,500 patient study of the cancer-detection technology. CeMines noninvasive molecular fingerprinting technology is extremely promising, and the idea behind this approach is brilliant, said Dr. Madis Metsis, principal investigator of the study now under way at Karolinska. The next step will be systematic and well-defined analyses of tumors in order to reach the ultimate goal of molecular fingerprinting--deciphering the molecular structure of individual tumors that will help us design specific diagnostic methods and drugs to treat cancer.

Reduced risk of prostate cancer among patients with diabetes mellitus

Although diabetes mellitus is associated with an increased risk of several malignancies, a negative association with prostate cancer is biologically most plausible. The epidemiologic evidence is, however, inconsistent, limited and based mostly on small studies. We present results from a large, population-based cohort study in Sweden, where we assessed prostate cancer risk among patients hospitalized for diabetes mellitus. We found no consistent trends in risk related to age at first hospitalization or to duration of follow-up. We did find a small, but significantly decreased risk of prostate cancer among men who had been hospitalized for diabetes mellitus.
Source: Int J Cancer 2002 Nov 20;102(3):258-61, Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO. Abstract:

Medarex Initiates Phase II Clinical Trials of MDX-010 for Metastatic Melanoma and Prostate Cancer

Medarex, Inc. (Nasdaq: MEDX) today announced the initiation of two Phase II clinical trials of MDX-010, one in patients with metastatic melanoma and one in patients with hormone refractory prostate cancer. The two randomized, multi-dose Phase II studies are designed to assess the potential anti-tumor activity of MDX-010. The metastatic melanoma Phase II trial will study MDX-010 both as a single agent and in combination with DTIC (dacarbazine). The trial is expected to initially accrue a total of 46 chemotherapy naive patients with metastatic disease. MDX-010 will be given in a regimen of four monthly intravenous infusions of 3.0 mg/kg alone or in combination with DTIC. Patients will be followed until tumor progression and will be evaluated based on objective tumor responses. Information For further information regarding MDX-010 and clinical trial information, please send an e-mail to information@medarex.com

Clinical results on high intensity focused ultrasound presented at congresses

EDAP TMS S.A., a global leader in the development, marketing, and distribution of a portfolio of minimally invasive medical devices for the treatment of urological diseases, announced that its High Intensity Focused Ultrasound (HIFU) subsidiary, EDAP S.A., participated in three international congresses. The third congress, the World Congress on Endourology (WCE), was held in Genoa, Italy. HIFU technology, applied to the treatment of localized prostate cancer, is being included in the official program. Lectures were given by two Ablatherm users during plenary and main sessions, in addition to the five posters the company had accepted.

AVI's Combination Antisense Strategy Inhibits Tumor Growth In Human Prostate Cancer Models

AVI BioPharma, Inc. announced a novel combination strategy in treating advanced stage hormone-refractory prostate cancer using AVI's NEUGENE(R) antisense. The strategy, tested in preclinical research, is explained in the November issue of The Prostate, 53(3): 200-10. AVI scientists used NEUGENE antisense to target both the c-myc gene and human chorionic gonadotropin (hCG), a hormonal growth factor, both of which have been implicated in the growth of prostate cancer. NEUGENE antisense inhibition of hCG and c-myc in combination caused a significant reduction of growth of human prostate cancer cells in cultures. In addition, this combination antisense therapy also inhibited growth of tumors transplanted to susceptible mice.

Post-Treatment Impotence Widespread

Few aspects of prostate cancer treatment arouse as much confusion -- or controversy -- as the rates of sexual dysfunction after various therapies. The results of a large federally funded study published this month in the journal Cancer are certain to fuel the debate about the sexual side effects of surgery and radiation. The study of more than 1,200 men treated at the Cleveland Clinic between 1992 and 1999 paints a bleak portrait, concluding that "the great majority of men . . . do not achieve a return to functional sexual activity."
Source: www.washingtonpost.com/wp-dyn/articles/A24646-2002Oct26.html

Online Insight for Men Who've Had a Prostatectomy

There's a new online calculator that helps forecast the future health of men who have had radical prostatectomy to treat localized prostate cancer. The calculator predicts the likelihood of a man's level of prostate-specific antigen (PSA) remaining low seven years after removal of the prostate gland. About 30 percent to 40 percent of men who have a prostatectomy experience an increase in their PSA level. That may indicate a recurrence of prostate cancer within five to 10 years after the surgery.
Source: www.ustoo.org/screamoutput/index.html

Vitamin D for Prostate Cancer

Though studies are not conclusive, researchers say vitamin D deficiency may play a role as a potential risk factor for prostate cancer. In fact, massive doses of the vitamin may help treat the disease. In a study out of Oregon Health & Science University, 25 percent of patients showed dramatic drops in their PSA levels. Most had their levels drop by 50 percent. Oncologist Tomasz Beer, M.D., tells Ivanhoe, "Taxotere alone works in about 40 percent of patients, we saw over 80 percent of patients respond to the combination, so we're very encouraged by those earlier results." In the next phase of the study, researchers are recruiting more than 200 patients at about 20 medical centers in the United States.
Source:  www.ivanhoe.com/channels/p_channelstory.cfm?storyid=4686

Cancer Therapy Causes Devastating Oral Complications

More than one million Americans will be diagnosed with cancer in the upcoming year, and approximately 40 percent, or 500,000, will develop serious oral complications as the result of their treatment. Although cancer therapies such as radiation, chemotherapy and bone marrow transplantation have become more powerful and therapeutically successful over the past 10 years, the cancer-fighting treatments affect healthy tissues as well. The mouth is a frequent site of acute and chronic side effects which can diminish quality of life for cancer patients and negatively affect treatment.
Source: www.agd.org/consumer/topics/oralcomplications/main.html

Herbal Extract May Compromise Prostate Cancer Chemotherapy Drug

PC-SPES, a dietary supplement taken by some men as a treatment for prostate cancer, may compromise the effectiveness of chemotherapeutic agents, such as paclitaxel, by interfering with microtubule polymerization, according to a study in the November 6 issue of the Journal of the National Cancer Institute.
Source: Journal of the National Cancer Institute, www.intelihealth.com/IH/ihtIH/EMIHC000/333/333/357699.html

Biphosphonate Reduces Bone Complications From Spread Of Prostate Cancer

In patients with advanced prostate cancer, the disease often spreads to the bone, causing pain, fractures, and spinal cord compression.
Source: Journal of the National Cancer Institute, www.intelihealth.com/IH/ihtIH/EMIHC000/333/333/356115.html

Researchers Find Gene That May Signal Deadly Form Of Prostate Cancer

In a discovery that could someday help guide treatment of men suffering from early stages of prostate cancer, researchers studying DNA in tumors say they have found a gene that predicts whether the cancer will develop into its most lethal form.
Source: www.intelihealth.com/IH/ihtIH/EMIHC000/333/333/356418.html

Heart Disease Gene Linked to Prostate Cancer

Researchers at Johns Hopkins, Wake Forest, and The National Human Genome Research Institute have implicated mutations in a "heart disease gene" in hereditary prostate cancer. The findings, which offer new evidence that at least some cases of prostate cancer may begin with an infection and inflammatory response, were published online September 16, 2002, in Nature Genetics.
Sources: www.ustoo.org/screamoutput/index.html , http://urology.jhmi.edu , www.hopkinskimmelcancercenter.org

Wake Forest-John Hopkins Team Discovers Prostate Cancer Gene

Scientists have discovered a gene that "may play an important role in prostate cancer susceptibility in both African-American men and men of European descent."
Source: www.ustoo.org/screamoutput/index.html

Novel Gene Product Facilitates Suicide Gene Tracking in Male Cancers

Medical researchers at the University of California School of Medicine in Los Angeles have discovered a novel gene product that enables doctors to track prostate cancer suicide gene therapy with a noninvasive imaging technique.
Source: www.ustoo.org/screamoutput/index.html

Casodex Reduces Disease, Tumor Progressions

The first major publication of the overall results from the world's largest prostate cancer treatment program shows that addition of Casodex (bicalutamide) to standard care cuts the risk of tumor progression by almost a half.
Source: www.ustoo.org/screamoutput/index.html

Dietary Change May Prevent Disease Progression

A fat-laden diet and high calcium consumption are both well-known suspected risk factors for prostate cancer. However, new findings from the Fred Hutchinson Cancer Research Center suggest that fat and calcium themselves may not cause prostate cancer, as previously thought, but instead may fuel its progression from localized to advanced disease.
Source: www.ustoo.org/screamoutput/index.html

Tackle Prostate Cancer

The Prostate Cancer Education Council (PCEC) and the National Football League are joining forces for a second year to "Tackle Prostate Cancer."

Prostate Cancer Awareness Week will be held September 15-21, 2002 at hundreds of sites across the country. That week free and low-cost prostate cancer screenings will be held at hospitals, clinics, health care centers, and private physicians' offices. The NFL will be publicizing the Week through a variety of media efforts For more information, visit
Source: www.pcaw.com/PDF/NFL_PSA.pdf

Louise Hay on the Prostate and Prostate Cancer

Louise Hay, in her book Heal Your Body, says that the prostate "Represents the masculine principle." And, to be healthy, one need "accept and rejoice in his masculinity." Where prostate problems come in is with one of the following beliefs: "Mental fears weaken the masculinity. Giving up. Sexual pressure and guilt. Belief in aging." To clear this dis-ease up requires one to truely believe one or more of the following new thought patterns: I love and approve of myself. I accept my own power. I am forever young in spirit."

Free or Low-Cost cPSA Tests During Prostate Cancer Awareness Week

Recent research shows that the use of the complexed prostate specific antigen (cPSA) test results in fewer false indications of prostate cancer than the traditional PSA test and could help avoid more than 44,000 unnecessary biopsies each year in the U.S. Men being screened during the 14th annual Prostate Cancer Awareness Week (PCAW), September 15-21, will have access to this additional form of the standard PSA blood test. During PCAW, more than 500 hospitals, clinics and private physicians will provide free or low-cost screenings to more than 100,000 men nationwide.

Prostate specific antigen (PSA), a protein produced by the cells in the prostate, has proven to be a useful marker for early detection of prostate cancer and in monitoring patients for disease progression and the effects of treatment. However, current PSA testing generates up to 60% "false positives" because PSA levels can also increase due to non-cancerous conditions of the prostate which are increasingly common as men get older. It can also generate "false negatives" since a significant number of cases of prostate cancer have been found in men whose PSA was "normal." Much research has focused on ways to improve the accuracy of PSA testing, and cPSA offers a new weapon in the fight against prostate cancer.
Source: http://209.35.73.106/pcaw/screening.asp

Golfer Bruce Fleisher Glad He Took Advantage of free PSA Test

Criticized by Hale Irwin and Tom Kite for withdrawing from the U.S. Open, Bruce Fleisher can live with his decision.

As it turned out, by not playing at Bethpage and then competing in the BellSouth Senior Classic in Nashville, Fleisher took advantage of a free physical exam at the tournament. The test revealed a high PSA (prostate specific antigen) number, three times higher than last year, which could indicate the presence of prostate cancer. Fleisher soon will undergo more tests.

"If I had not come here and done the exam, I probably would not have done it again until next year," Fleisher said, "and who knows what would have happened?"

Fleisher is the U.S. Senior Open champion, and Irwin and Kite said he should have represented the Senior Tour at Bethpage. But Fleisher disagreed.

"It's not copping out," Fleisher said. "I think Tom Kite and Hale Irwin gave an excellent representation of the Senior Tour, if that's what they want. Some guys call it ego. I call it very sensible."

Prostate Surgery Preserves Potency, But HMOs Are Putting Up Barriers

People contract with HMOs knowing that they are more restrictive than other forms of insurance. But whether an HMO meets its contractual obligations if its network doctors can't come close to matching the results of other surgeons is a tough question to answer "There is no legal or contractual requirement that the Health Plan send their members to an academic medical center or to an out-of-plan physician who has performed more procedures than a qualified physician,"
Source: http://ustoo.org/WSJ061902.pdf

Into the Light - Survivors' groups and researchers raising awareness of prostate cancer

What a man doesn't know could hurt him. When it comes to prostate cancer, the No. 1 nonskin cancer among men, ignorance can be deadly. That's why so many survivors are working to push this stigmatized and misunderstood disease into the public consciousness.
Source: www.journalnow.com/wsj/living/MGBZZ5U1L2D.html

An Update On Brachytherapy

There's a new Web site for people interested in learning more about brachytherapy, an internal radiation treatment for different kinds of cancer. Brachytherapy has been used for decades and involves planting of radioactive "seeds" inside the cancerous tissue to attack the cancer. The treatment often has fewer and less severe side effects than other therapies, according to the American Brachytherapy Society (ABS). Currently, brachytherapy is used primarily to treat prostate, breast and cervical cancers. Other methods of treating these cancers include surgery, chemotherapy and external beam radiation therapies. To see the site, go to the
Source: American Brachytherapy Society, www.americanbrachytherapy.org

A patient's view

Hal Ackerman's graphic account of his encounter with prostate cancer in My Generation ($2.95) may make some men cringe, but it also may send them to their doctor for an exam. Ackerman, 50, opted for hormone-deprivation therapy _ ``chemical castration'' _ instead of surgery. ``Not only is the sex drive gone,'' he writes, ``but the desire for the sex drive is gone. Women whose bodies in the past would have stimulated longing and desire now generate no more response than the sight of uncovered furniture.'' That's the downside. The upside is that Ackerman has been cancer-free for more than a year after subsequent radiation treatment.

Vasectomy Link to Prostate Cancer Dismissed

Dr Brian Cox and colleagues from Dunedin School of Medicine, Wellington School of Medicine and the University of Otago in New Zealand looked at more than 2,000 men, almost half of whom were newly diagnosed prostate cancer patients, to examine whether a link between this cancer and vasectomy existed. New Zealand was considered to be an ideal country in which to conduct the investigation because of its high incidence of vasectomy and its mandatory policy on cancer reporting. The men, aged between 40 and 74, had all been married at some time and were interviewed via telephone about previous illnesses, vasectomies, smoking and alcohol consumption, prostate specific antigen testing, rectal examination, previous urological symptoms, family history of cancer and socio-demographic characteristics. The researchers found that there was no increased risk of the disease among men who had undergone a vasectomy 25 or more years before they were interviewed. Furthermore, vasectomy carried no greater risk of prostate cancer, even after adjusting for social class, geographic location, religion and family history. "Since vasectomy is so common in New Zealand and all new prostate cancers there must be reported to its National Cancer Registry, that's where you would expect to find a link between the two if one exists," said Dr Steven Kaufman of the National Institute of Child Health and Human Development's Contraception and Reproductive Health Branch. He added, "Also, although the study was more than large enough to detect an increased prostate cancer risk associated with vasectomy, none was found." The findings appear in the Journal of the American Medical Association

Modified tomato may protect against cancer

Scientists in the US have modified a tomato genetically so that it contains higher than normal levels of a chemical that may offer protection against cancer. It was developed at Purdue University in Indiana by accident as scientists sought higher quality strains of the fruit. Tomatoes contain various antioxidants, including lycopene, which is associated with reduced cancer risk. The new strain, which is modified with a yeast-derived gene, contains between two and three-and-a-half times the lycopene of the average tomato.
Source: news.bbc.co.uk/hi/english/health/newsid_2054000/2054381.stm

Return of Prostate Cancer First Seen by MRI, Not Biopsy

A study has found that dynamic magnetic resonance imaging (MRI) can detect prostate cancer recurrence even before it can be detected by biopsy. The finding was presented at the annual meeting of the American Roentgen Ray Society in Atlanta (GA, USA). The study, conducted by researchers at Sapporo Medical University (Sapporo, Japan), involved 21 patients who had a rising prostate-specific antigen (PSA) level following radical prostatectomy. All patients had an ultrasound-guided biopsy that came back negative, but the MR images in 17 of the 21 patients indicated local recurrence. Additional biopsies to confirm recurrence would have wasted precious time, during which patient PSA levels would have continued to rise. Therefore, the researchers conclude that prostate cancer patients with a rising PSA following prostatectomy should first have an MRI to determine if their cancer has returned. "MR is allowing us to detect the recurrence earlier, when the cancer can be more effectively treated with radiation therapy," says Miki Takeda, M.D., the lead author of the study. In fact, 15 of the 17 patients in the study were treated with radiation therapy, and seven are now considered cancer free. "Dynamic MR imaging contributed to these results," adds Dr. Takeda

Prostate Cancer Cell Growth Inhibited by Red Wine

Studies have suggested that environmental and dietary factors have an important influence on the development of prostate cancer, as witnessed by the higher rate of the malignancy among Japanese men living in the US compared to those in Japan. Mediterranean countries, where red wine is commonly consumed, have lower rates of prostate cancer than other western countries. Dr I Romero and colleagues from Getafe University Medical Centre in Spain investigated five polyphenols - quercetin, morin, rutin, gallic acid and tannic acid - found in red wine to determine whether they exerted an effect on the growth of the LNCaP cell line. LNCaP cells were obtained and cultured in vitro before each of the five polyphenols was added to separate dishes and incubated for 96 hours. Rates of proliferation and apoptosis were assessed using colorimetric and cell-death detection assays, respectively. The cultures were sampled at 24, 48 and 72 hours, and cell proliferation was also assessed after 96 hours. The researchers found that 5 and 10mol/l of gallic and tannic acid and quercetin, and 50 and 75mol/l of morin and rutin, all significantly reduced rates of cell proliferation compared to control plates. Rates of apoptosis inhibition varied between polyphenols, with gallic acid, tannic acid and rutin bringing about significantly greater rates of cell death compared to controls. The effects of morin were only observed at 72 hours, and those of quercetin within the first 48 hours. Dr Romero and colleagues conclude that these polyphenols, which are always present in red wine, significantly inhibit prostate cell proliferation and activate apoptosis. Writing in the BJU International, they add, "These results provide a rationale for studying the in-vivo effects of these nutrients, with the potential for formulating future recommendations about the intake of these substances as chemopreventive agents." Reference: Romero et al, BJU International 2002; 89:950-954

Cancer's Effect on Relationships under Scrutiny

The study, funded by Cancer Research UK and led by specialist cancer nurse Lynne Colbourne, will involve 30 patients with either prostate or testicular cancer and their partners. Ms Colbourne will follow the couples from diagnosis and assess how survivors feel their lives changed following successful treatment. The findings should help nurses and other health professionals give better support to prostate and testicular cancer patients and their families, says Ms Colbourne. An earlier, smaller study showed that men who survive testicular cancer tend to trivialise the event and want to return to normal life as soon as possible. In contrast, women preferred to discuss what was happening with their friends - an approach that often caused conflict within the relationship. "Recovering patients were constantly in fear of the cancer returning and they found that difficult enough without taking on board the fear of their partner," says Ms Colbourne. Patients also found it distressing that when they reported even the smallest abdominal pain, wives or partners would insist they had it checked, says Ms Colbourne. Some women said that their husbands had become short-tempered after cancer treatment and some experienced sexual difficulties, although cancer had not had a detrimental effect on the couples' sex lives in the majority of cases. Ms Colbourne's study will examine in greater depth the different coping strategies employed by men and women, and what adjustments are made to the relationship. Jamie Spencer, a 34-year-old quantity surveyor from Nottingham who was diagnosed with testicular cancer in 1995, says his experience put a strain on his relationship. "When I was going for monthly checkups I became very stressed for two weeks beforehand and then I would be elated for two weeks afterwards," he says. Although Jamie now feels that he has beaten his cancer, he says his wife worries that the cancer is returning at the slightest sign of any illness. According to Cancer Research UK, around 22,800 men are diagnosed each year with prostate cancer and the majority of cases occur in men over 70. Testicular cancer is the most common cancer in men aged between 15 and 45, with around 1,900 cases diagnosed in the UK each year.

Prostate Tissue Could Treat Bone Disease

A team from Ohio State University's Comprehensive Cancer Center point out that, unlike other cancers, when prostate cancer spreads to the bones it stimulates growth. When most other cancers spread to the bones, they cause them to crumble, resulting in pain and debilitation. Dr Tom Rosol, a vet at the centre, says that up till now it has been difficult to find out why prostate cancer has this effect on bone because of the problem of finding a suitable animal model. Whenever scientists put human prostate cells into animals they behave differently to the way they do in humans, he says. He decided to test whether healthy prostate tissue, in addition to cancerous tissue, was capable of sending growth signals to the bone. And he used dogs' healthy prostate tissue as a means of testing his hypothesis as they are the only animals, other than humans, that develop cancer of this gland. Small amounts of prostate tissue obtained from dogs were inserted under the skin of adult nude mice, which were observed for two weeks. The results left researchers "shocked", says Dr Rosol. Within two weeks the density of the skullcap or calvaria of the mice had almost doubled. "This was really exciting, not just because of the speed of the reaction, but because there are really very few things in nature that induce bone growth," says Dr Rosol. While he says it is unclear what causes the bone to form he suggests the probability is that it is a "complex mix of growth factors", such as a parathyroid hormone-like protein and endothelin-1, which act alongside receptive agents in the hosts' bone. His team is currently working with a drug designed to block endothelin-1 activity and they believe it may be working. Dr Rosol says that there is a need to develop new and workable animal models to improve understanding of cancer. But he says that a process such as prostate cancer metastasis may hold the clue to an effective treatment for diseases such as osteoporosis that involve bone destruction. "What is devastating for a prostate cancer patient may be a source of hope for someone with osteoporosis," adds Dr Rosol. Source: The Prostate

Limiting PSA Testing To Men with a Family History of Prostate Cancer "Misses Most Prostate Cancers"

Researchers at the Finnish Cancer Registry in Helsinki say that, despite some evidence that men with a family history of prostate cancer are more likely to develop the disease, limiting screening efforts to these men will result in doctors missing many cases of the disease. Only six per cent of prostate cancer cases would have been detected in a study of more than 20,000 men, if testing for prostate specific antigen (PSA), a protein linked to prostate cancer, was restricted to men with a family history of the disease. The research is reported in the Journal of Clinical Oncology.

Revolution in Prostate Therapy Led by Microwave Thermotherapy

One of the hottest areas in urological therapies comprises testing and treatment for both benign prostatic hyperplasia (BPH) and prostate cancer. This area, consisting of therapies that often can be used to treat both disorders, is effectively driving much of the U.S. urological products market, according the June 2002 issue of the widely read medtech industry publication, "MedMarkets."
Source: www.ustoo.org/screamoutput/index.html

Scientists Develop Tomato that Packs More Cancer-Fighting Punch

Forget the attack of the killer tomato, this is the attack of the healthy tomato: A team of scientists has developed a tomato that contains as much as three and a half time more of the cancer-fighting antioxidant lycopene.
Source: http://www.ustoo.org/screamoutput/index.html

Dogs Key to Understanding Advanced Prostate Cancer

When some of the most common cancers spread, they often head for the bones. Once there, they typically eat away the good, strong tissue, leaving a soft and crumbly structure in their wake. It is a painful and debilitating condition. But prostate cancer is different. Unlike any other cancer, when prostate cancer spreads to the bones - as it does in 80 percent of all advanced cases - it actually stimulates new bone to grow, not erodes it.
Source: www.ustoo.org/screamoutput/index.html

Zometa Effective for Debilitating Bone Complications

Zometa (zoledronic acid for injection) is effective for the treatment of potentially debilitating skeletal related events from bone metastases in prostate cancer patients, according to data presented at the 97th annual meeting of the American Urological Association (AUA) in Orlando, Florida.
Source: www.ustoo.org/screamoutput/index.html

Facing Fears: Prostate Cancer Screening

Screening for prostate cancer is crucial, since the disease often exhibits no symptoms, and is most effectively treated when caught early. Caucasian men are advised to visit their doctors for screening beginning at age 50, and African American men and men with a family history of prostate cancer, at age 40. Below, medical experts Dr. Daniel Shasha and Dr. Robert Salant review the two most important tests used for prostate screening-and describe what to expect when you go see your doctor.
Source: www.ustoo.org/screamoutput/index.html

BYU Study Finds Prognosis Is Worse for Prostate-Cancer Patients in Their 40s

Prostate cancer's deadly grip is worse for men in their 40s even though the disease is still considered rare in anyone younger than 50, according to a Utah-led study.

The findings raise more questions than answers, the authors say, because race and tumor stage made little difference in the poorer prognosis.

"It may be that younger men diagnosed with prostate cancer have a more difficult time adjusting to their diagnosis psychologically," says the study authors, Ray Merrill and Justin Bird, researchers at the Provo-based Brigham Young University.

Yet the BYU team, part of the College of Health and Human Performance, says more research is needed to discover exactly why prostate-cancer prognosis is worse in the 40-49 age group compared with the 50-79 group. Men 80 years and older, like the younger group, also had a poorer prospect of recovery.

The study appears in a recent issue of the journal Cancer Causes and Control. Data was gathered from nearly 300,000 prostate-cancer patients in five U.S. states (Utah, Connecticut, Hawaii, Iowa and New Mexico) and in four major cities (Atlanta, Detroit, San Francisco and Seattle).

Possibly "sexual potency may be a more important concern for men of younger ages, and this may deter them from selecting treatment, influence their treatment choice or delay initiation of treatment," the study says.

The disease signals an uncontrolled malignant growth of cells in the gland located just below the male bladder. In U.S. men, prostate cancer is the second leading cause of death; it can be diagnosed with a PSA test of the blood or through a physical exam called digital rectal exam or DRE.

Controversy surrounds the idea of encouraging prostate screening in younger men because data, including the BYU study, fails to show any early diagnostic benefit among the general male population, the authors said.

The American Cancer Society describes prostate cancer as a latent disease, hidden but waiting to develop. The group cautions against raising undue alarm by testing before age 50 unless there is father, brother, or son diagnosed with prostate cancer at a young age.

New Predictive Marker Found for Prostate and Colon Cancer

A protein that interacts with the gene for Huntington's disease could also help physicians diagnose and more effectively treat patients with two of the most common and deadly forms of cancer, according to a new University of Michigan study.

Absent in normal prostate and colon epithelial cells, but found in large amounts in prostate, colon and other tumor cells, it is called huntingtin interacting protein or HIP1. The protein has never before been associated with any type of cancer. (Editors: Note "huntingtin" is correct spelling.)

"Anytime you find a true marker for cancer, it's surprising," says Theodora S. Ross, M.D., Ph.D., an oncologist in the U-M's Comprehensive Cancer Center and an assistant professor of internal medicine in the U-M Medical School. "But HIP1 also is unusual, because it seems to be such a strong prognosticator, especially for prostate cancer."

Results of U-M research on HIP1's relationship to human prostate and colon cancer were published August 1 in the Journal of Clinical Investigation.

"We don't find significant HIP1 expression in normal prostate epithelial cells, but as prostate cancer develops and progresses, we see a steady increase in HIP1 expression," Ross explains. "HIP1 was expressed in 50 percent of tumors from patients in the earliest stages of cancer, 88 percent of tumors from patients with localized prostate cancer, and 100 percent of patients with metastatic prostate cancer."

"High levels of HIP1 were present in every stage of colon cancer," Ross adds. "In melanoma, breast and ovarian cancers, the expression patterns varied, but HIP1 was consistently over-expressed."

During her post-doctoral fellowship at Boston's Dana-Farber Cancer Institute, Ross cloned the protein from bone marrow cells of a patient with leukemia. Since joining the U-M Medical School three years ago, she has focused on nothing but HIP1 and its relationship to an important cellular trafficking and signaling system called the clathrin-mediated trafficking pathway. Cells use this system to remove old receptors and signaling molecules on cell surfaces and replace them with new molecules.

The HIP1 protein appears to be involved in this process, according to Ross, along with another protein called htt, which is expressed by the mutated gene responsible for Huntington's disease -- an inherited, progressive form of dementia. Although both proteins are found in parts of the cell where movement of material occurs, their exact role is unknown. The connection to the Huntington's gene could be significant, however, "because people with Huntington's rarely get cancer," Ross adds.

"This is a new pathway in tumorigenesis; no one else is working with it in this context," Ross says. "Our paper is the first demonstration of a connection between tumor formation and a protein involved in this cell trafficking pathway."

Ross' laboratory is now trying to understand the relationship between HIP1 and cancer cells. "Originally, I thought HIP1 was a tumor suppressor gene, but it could be a survival factor that prevents cancerous cells from dying or an oncogene causing normal cells to become cancerous. It could have varying effects, depending on the cell or tissue type. More research is needed to know for sure," she says.

Results included in the JCI paper showed that when U-M researchers created a mutant version of HIP1 by knocking off one segment of the protein, the result was massive cell death. "When we made a mutant that interfered with the function of the normal protein, the cells died, which suggests that HIP1 is necessary for cell survival," she says.

If scientists can discover the functional relationship between HIP1 and cancer, Ross believes it should be possible to develop agents that could kill prostate and colon tumor cells without harming the normal epithelial cells lining the inside of these organs.

In her study, Ross first measured levels of HIP1 expression in 60 cancer cell lines and a tissue microarray of primary tumors from the National Cancer Institute, which included hundreds of tissue samples from colon, breast, melanoma, ovarian, prostate, kidney and lung cancer. "We never could have looked at all these different tumors without the NCI microarray; it's an amazing resource for investigators," Ross says.

To quantify HIP1 expression in different stages of prostate cancer, U-M researchers used tissue samples from the U-M Prostate Specialized Program of Research Excellence (SPORE) tumor bank, funded by the National Cancer Institute. Tissue samples of various stages of colon cancer were provided and interpreted by Peter C. Lucas, M.D., Ph.D., U-M lecturer in pathology.

Research on the genetic and molecular profile of prostate cancer is part of a major initiative underway in the U-M Comprehensive Cancer Center. Its goal is to link molecular genetics and proteomics with clinical outcome for all types of cancer.

The research study was funded by the Huntington's Disease Society of America, the National Institute of General Medical Sciences and the Cancer Research Fund of the Damon Runyon Foundation.

Dinesh S. Rao, Ph.D., a U-M post-doctoral fellow, is first author of the study. In addition to Lucas, other U-M Medical School collaborators include Martin G. Sanda, M.D., associate professor of surgery and of internal medicine; Mark A. Rubin, M.D., associate professor of pathology and surgery; Ikuko F. Mizukami, Ph.D., research associate; and graduate students Teresa S. Hyun and Priti D. Kumar.

Winning His Battle

Speaking from his 10th-floor, ocean-side San Diego condo Tuesday, Jerry Tarkanian was, well, Jerry Tarkanian.

Alert and optimistic, the former Fresno State coach didn't sound like a 71-year-old in his second week of radiation treatment for prostate cancer. An all-encompassing conversation roamed from his health to the latest basketball gossip to books. Yes, books.

"I'm trying to read a book called 'The Trust Fund'," Tarkanian said. "I used to only read [basketball] books. I'm not like that anymore."

He didn't even bring any UNLV or Fresno State game tapes to his Southern California home, where he will spend weekdays for the next seven weeks recovering from treatment. Each morning, Tarkanian receives about 15 minutes of treatment at a Scripps medical facility in San Diego.

Then he retreats to his condo to read and rest.

"I feel good," he said. "After the treatment I get tired and usually take an afternoon nap. But that's OK."

Tarkanian was warned of potential prostate cancer in August, but initially didn't worry about it. Then, after the season, he decided to tend to it while the prostate cancer -- the leading cause of cancer deaths in men aged 55 or more -- was in the early stages.

Many luminaries in the basketball world have expressed sympathy for the man who viewed himself as the NCAA's No. 1 target. NBA personality Charles Barkley wished Tarkanian well on the national TNT broadcast of the NBA draft after former Fresno State center Melvin Ely was selected. Adidas bigwig Sonny Vaccaro said last week his thoughts and prayers were with his friend.

"The treatment is going fine," said son and former Bulldogs assistant Danny Tarkanian, who now lives in Las Vegas. "Doctors told him they think it is contained in the prostate. My dad says he is not feeling any pain."

Asked if he felt apprehension about receiving treatment, Tarkanian said. "At my age, you expect something [to be wrong with you]. ... They said they got it early. This is supposed to cure it."

Tarkanian also said he and his two sons, Danny and George, will establish a youth basketball academy in Las Vegas. The Tarkanians will hold camps for elementary school-aged kids this month to raise money for the academy.

Helping out will be former UNLV players, including Sam Smith, Robert Smith and Freddie Banks.

Tarkanian has his weekends free to visit relatives and friends. He said he will be in Fresno in two weeks.

He also said he has plans to attend the Oct. 26 Florida State-Notre Dame football game in Tallahassee, Fla., with friends.

"He is doing well," George Tarkanian said. "The treatment is not really affecting him too much."
Source: www.fresnobee.com or the reporter can be reached at eprisbell@fresnobee.com

Got Soy? New Research Focusing on Soy Role in Prevention of Prostate Cancer in U.S. Males.

Parade Magazine, the weekly newspaper supplement, is the latest publication to report favorably on the role of soyfoods in helping prevent prostate cancer. Health columnist Dr. Isadore Rosenfeld, writing on "Medical News That Matters," says "several recent and current studies have focused on preventing prostate cancer," with soy intake featured in the research.
Source: www.ustoo.org/screamoutput/index.html

Genetic Link to Prostate Cancer Found

The genetic make-up of a man's immune system can have a direct bearing on his chances of developing prostate cancer, researchers say.
Source: www.ustoo.org/screamoutput/index.html

Prostate Cancer Isn't Just a Guy Thing

Helping your mate cope with prostate cancer can include far more than just holding his hand for comfort. From encouraging him to get tested for prostate cancer to helping him get the best care if he does have the disease, a woman can immeasurably improve the quality of her partner's life. That's the opinion of Desiree Lyon Howe of Houston, whose husband, Richard Howe, is a prostate cancer survivor and one of the country's leading lay experts on the disease.
Source: http://www.ustoo.org/screamoutput/index.html

Study Shows Cancer Cells are Vulnerable in New Ways

Vitamin E, a compound suspected of playing a role in preventing prostate cancer, interferes with two proteins that play a central role in the development of the disease. This is the report of scientists at the University of Rochester Medical Center who published their findings in the May 28, 2002, issue of the Proceedings of the National Academy of Sciences USA.
Source: www.ustoo.org/screamoutput/index.html

Fighting Prostate Cancer: 'Go Get a Checkup'

With his three daughters all employed in the medical field, North Jacksonville resident Charles Sapp had a bit more than luck on his side more than a year ago when his prostate cancer was caught in the early stages.
Source: www.ustoo.org/screamoutput/index.html

TIG1 Identified As Tumor Suppressor Gene For Prostate Cancer

A new study has identified tazarotene-induced gene 1 (TIG1) as a possible tumor suppressor gene for prostate cancer, and experimental results suggest that decreased expression of the gene may play a role in the progression of prostate cancer.
Source: Journal of the National Cancer Institute, www.intelihealth.com/IH/ihtIH/WSIHW000/333/8012/348096.html

Lance Armstrong Inspires Cancer Patients

Lance Armstrong was diagnosed with testicular cancer at the age of 25. A few days later, he learned the cancer had spread to his brain. He underwent surgery and chemotherapy. Three years later, he rode a bicycle more than 2,200 miles to win the Tour de France.

Armstrong insists the cancer was the best thing that ever happened to him, because it taught him about the strength of the human spirit, and the love of family and friends. One month after his chemotherapy ended, he met his wife. Using sperm removed before his surgery, he and his wife conceived a son, who is now 3 years old.

Lance Armstrong's recent victory in the grueling Tour de France has inspired cancer victims around the world. Upon winning the race, Armstrong said, "Regardless of one victory, two victories, four victories, there's never been a victory by a cancer survivor. That's a fact that hopefully I'll be remembered for."

John Romano, columnist for the St. Petersburg Times, recently wrote a column that describes the meaning of Armstrong's victory to cancer survivors:
Source: